Abion

Abion was founded in 2007 and listed on KOSDAQ in September 2021 through the technology special-listing track as a biomarker-based oncology drug developer.

Its core pipeline consists of the non-small cell lung cancer (NSCLC) drug Vabametkib (ABN401), the Claudin3 (CLDN3)-targeting antibody platform ABN501, ABN202 built on the interferon-beta antibody-conjugate (iRAC) platform, and the interferon-beta-based broad antiviral candidate ABN101.

Revenue is small in absolute terms, coming mainly from government research service contracts rather than commercialized drug sales. The business model is to validate candidate efficacy and commercial potential before out-licensing or co-developing with global pharmaceutical partners.

In 2025, Abion out-licensed ABN501, covering five target antibodies including Claudin3, to an undisclosed global partner for a total contract value of $1.315 billion, with a non-refundable upfront payment of $5 million per target antibody, totaling $25 million.

Unlike Claudin18.2, which is mainly relevant in gastrointestinal cancers, Claudin3 shows high expression across a broader range of solid tumors including NSCLC, giving it wide indication potential, though achieving antibody selectivity is technically difficult and has led many companies to abandon development of this target.

Vabametkib is in a global Phase 2 trial targeting NSCLC patients with MET exon 14 skipping mutations, and independent blinded central image review (BICR) data presented at ASCO 2026 showed a 55% objective response rate and a 14.5-month median duration of response.

ABN202, built on the iRAC platform, is being developed as a next-generation immuno-oncology agent targeting resistance to TROP2-directed antibody-drug conjugates (ADCs), competing mainly against other clinical- and preclinical-stage biotechs without commercialized products yet.

Abion's annual revenue remained minimal at KRW 2.5 billion in 2022, KRW 1.3 billion in 2023, KRW 0.8 billion in 2024, and KRW 0.9 billion in 2025, reflecting the absence of commercialized drug sales.

Operating losses widened from KRW 25.2 billion in 2022 to KRW 31.3 billion in 2023 and KRW 34.1 billion in 2024, before narrowing to KRW 19.4 billion in 2025.

Net loss attributable to owners followed a similar pattern, rising from KRW 19.9 billion in 2022 to KRW 29.2 billion in 2023 and KRW 43.4 billion in 2024, then declining to KRW 29.1 billion in 2025.

Because revenue is so small, operating margin was deeply negative every year — -1,004.1% in 2022, -2,452.5% in 2023, -4,484.2% in 2024, and -2,201.0% in 2025 — reflecting an early-stage biotech cost structure where R&D-driven fixed costs vastly exceed thin revenue.

Year-end 2025 equity rose sharply to KRW 68.4 billion from KRW 28.1 billion at end-2024, and the debt ratio fell from 126.7% to 17.9%, consistent with the cash inflow from the ABN501 licensing upfront payment and other capital-raising activity.

Operating cash flow, however, remained negative every year — KRW -19.9 billion in 2022, KRW -26.9 billion in 2023, KRW -28.1 billion in 2024, and KRW -33.0 billion in 2025 — underscoring continued dependence on external financing.

On a quarterly basis, losses widened from KRW 0.21 billion revenue and a KRW 4.4 billion operating loss in 2025Q2 to a KRW 5.6 billion operating loss in 2025Q4 on just KRW 0.07 billion revenue, before revenue rose to KRW 0.57 billion in 2026Q1 alongside a KRW 6.5 billion operating loss, then fell back to about KRW 0.14 billion in 2026Q2 with a KRW 4.3 billion operating loss and a KRW 9.0 billion net loss attributable to owners.

Over the trailing four quarters (2025Q3–2026Q2), the cumulative net loss attributable to owners was about KRW 28.4 billion, indicating that despite quarter-to-quarter volatility, large-scale annual losses have persisted.

In the NSCLC treatment market, MET exon 14 skipping is a relatively rare subtype, but approved competing targeted therapies already exist, making differentiation in efficacy and safety critical for a later entrant like Vabametkib.

IV Research noted in a June 2026 analysis that Vabametkib showed superior safety data versus competing drugs and cited the potential for U.S. FDA accelerated approval.

The Claudin3-targeted therapy field has developed more slowly than the gastric-cancer-focused Claudin18.2 space, as achieving antibody target selectivity is difficult and many companies have abandoned development, though the area is being revisited amid the broader ADC development trend.

The ADC-resistance space targeted by the iRAC platform is seen as an area of growing demand for new treatment options as TROP2-directed and other targeted ADCs expand in clinical use.

Among domestic biotechs with a similar platform-licensing business model, companies such as Y-Biologics, EuBiologics, Angiolab, and Qurient are cited as comparables. The broader KOSDAQ biotech sector has been characterized as one where share prices react more to clinical or licensing events than to reported earnings.

In the KOSDAQ market, a newly introduced 'penny-stock' rule in the second half of 2026 — triggered when a share price stays below KRW 1,000 for an extended period — has exposed numerous small-cap biotechs to administrative-issue designation risk, affecting capital market access across the sector.

Abion plans to attend the World Conference on Lung Cancer (WCLC 2026) in Seoul on September 12–15, 2026, where it will share global Phase 2 results and future strategy for Vabametkib and continue licensing discussions with potential partners.

At the same event, the company said it will introduce its next-generation immuno-oncology platform iRAC to expand global partnering.

Earlier, in June 2026, Abion officially launched the iRAC-based candidate ABN202 at BIO USA and presented related preclinical data at AACR 2026, stating it confirmed the candidate's potential to overcome resistance to TROP2-directed ADCs.

The company also said it plans to unveil a new iRAC-platform candidate combining an EGFR antibody with interferon-beta in the second half of 2026.

It recently completed U.S. patent registration for the core source technology of the iRAC platform, saying this strengthens its intellectual property base for global commercialization. According to a September 2025 report, the company had set a target of filing for U.S.

FDA accelerated approval for Vabametkib sometime in 2028 and said it would accelerate clinical progress toward that goal. These plans, however, remain subject to change depending on partner contract execution, additional clinical data, and regulatory discussions.